Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Caribou Biosciences (CRBU) EBITDA Margin (2020 - 2025)

Caribou Biosciences has reported EBITDA Margin over the past 6 years, most recently at 671.86% for Q4 2025.

  • Quarterly EBITDA Margin rose 106256.0% to 671.86% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1328.77% through Dec 2025, up 16093.0% year-over-year, with the annual reading at 1328.77% for FY2025, 16093.0% up from the prior year.
  • EBITDA Margin was 671.86% for Q4 2025 at Caribou Biosciences, up from 1250.91% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 41.62% in Q3 2023 and troughed at 2033.18% in Q2 2025.
  • The 5-year median for EBITDA Margin is 825.1% (2021), against an average of 1020.18%.
  • Year-over-year, EBITDA Margin tumbled -161728bps in 2024 and then soared 106256bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 727.39% in 2021, then rose by 1bps to 717.01% in 2022, then crashed by -31bps to 941.37% in 2023, then crashed by -84bps to 1734.42% in 2024, then soared by 61bps to 671.86% in 2025.
  • Per Business Quant, the three most recent readings for CRBU's EBITDA Margin are 671.86% (Q4 2025), 1250.91% (Q3 2025), and 2033.18% (Q2 2025).